HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00635921

Ziprasidone for Borderline Personality Disorder

This study is completed in Spain. It is testing ziprasidone for Borderline Personality Disorder.

Personality disorders, Borderline personalityDrugFrom 18 Years to 45 Years
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 45 years.

Listed locations
Barcelona, SpainSee all locations and recruitment

Compensation and expense reimbursement have not been verified for this summary.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateMarch 2004
Recruitment status
Completed
Enrollment listed in the registry
60
Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Spain
Age range
From 18 Years to 45 Years
Official registry ID
NCT00635921
Official title
Ziprasidone in the Treatment of Borderline Personality Disorder: A Double-Blind, Placebo-Controlled, Randomized Study

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT00635921. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Completed

Barcelona

Checked Official study record (opens in a new tab)
Registry details
Registry conditions (original wording)

Borderline Personality Disorder

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including ziprasidone and Placebo.

Who can participate?

Listed age limits: 18 years to 45 years.

Is this study still recruiting?

The registry lists this study as completed.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.

Drug study icon
CompletedEUCTR 2020-003469-20

A double blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population (PORTICO)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.